NCT01480310View on ClinicalTrials.gov

Study to Investigate the Safety, Pharmacokinetics, and Immunogenicity of Subcutaneous MCAF5352A in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

23

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions

Healthy Volunteer

Interventions

DRUG

MCAF5352A

may receive up to 3 subcutaneous doses of MCAF5352A

DRUG

Placebo

may receive up to 3 subcutaneous doses of placebo

Trial Locations (1)

G1P 0A2

Québec

Sponsors

Lead Sponsor

Genentech, Inc.

All Listed Sponsors

lead

Genentech, Inc.

INDUSTRY